INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Whether the Sale of CoLucid Pharmaceuticals, Inc. to Eli Lilly & Co. for $46.50 Per Share is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--

The following statement is being issued by Levi & Korsinsky, LLP:

To: All Persons or Entities who purchased CoLucid Pharmaceuticals, Inc. CLCD stock prior to January 18, 2017.

You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of CoLucid Pharmaceuticals, Inc. to Eli Lilly & Co. LLY. Under the terms of the transaction (valued at approximately $960 Million) CoLucid Pharmaceuticals, Inc. shareholders will receive $46.50 for each share of CoLucid Pharmaceuticals, Inc. they own. To learn more about the action and your rights, go to:

http://zlk.9nl.com/CoLucid_CLCD

or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut, California, and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170202006121/en/